36results about How to "Strong target specificity" patented technology

The invention discloses an LRFFT2 cell. According to the LRFFT2 cell, human peripheral blood is used for carrying out ctDNA sequencing or carrying out whole exome sequencing on tumor tissue, mutationsites are screened out for antigen epitope prediction, and mutant polypeptide expression gene sequences are connected and synthesized; meanwhile, a lentivirus vector is constructed, lentivirus is packaged, an APC cell is transfected, the modification of a specific LV cell is completed, co-culture is carried out with a PBMC separated from the peripheral blood in vitro, effective polypeptide is screened out, and the second impact of stimulation of the effective polypeptide is accurate, so that a common T cell is transformed into an RFF cell with more accurate killing capability; transformation is carried out by utilizing a TCR-T technical principle; and immunosuppressive signal sealing is carried out on the transformed T cell in vitro by using an antibody drug, so that the specific killing Tcell is accurately protected from in-vivo suppression, and the killing force of the T cell on a tumor cell is improved, and therefore the LRFFT2 cell with better attack and defense functions is obtained. The LRFFT2 cell can be widely applied to individualized accurate treatment of solid tumors.

The invention belongs to the field of biotechnology, and particularly relates to a construction method of HAFFT1 cells. According to the method, small-molecule-modified polypeptide-stimulated cells are modified through a TCR-T technology. The modified T cells are subjected to immunosuppressive target pot knockout, specific killer T cells are accurately protected and prevented from inhibition in vivo, and the killing ability of the T cells to cancer cells is improved. The proportion of specific T cells (TCR+) recognizing tumor antigens is more than 80% in the HAFFT1 modified cells.

The invention provides a construction method of LRFFT2 cells; human peripheral blood is used for ctDNA sequencing or tumor tissues are used for full exon sequencing, mutant sites are screened out forepitope prediction and are connected to synthesize a mutant polypeptide expression gene sequence; at the same time, a lentivirus vector is constructed, lentiviruses are packaged, APC cells are transfected, the transformation of specific LV cells is completed, the transformed specific LV cells are co-cultured with PBMC isolated from the peripheral blood in vitro, and effective polypeptides are screened out; through precise effective second shocking stimulated by the polypeptides, ordinary T cells are transformed into RFF cells with more precise killing ability; transformation is preformed by aTCR-T technical principle; the transformed T cells are subjected to immunosuppressive signal sealing with antibody drugs in vitro, the specific killer T cells are precisely protected from inhibition in vivo, the killing ability of the T cells to tumor cells is improved, and the LRFFT2 cells with both attack and defense are obtained. The LRFFT2 cells can be widely applied in individualized and precise treatment of solid tumors.

Patient peripheral blood is used for ctDNA sequencing or tumor tissue is used for whole exon sequencing, mutation sites are screened to be subjected to epitope presequencing, and connection and synthesis are performed to obtain a mutation polypeptide expression gene order. Besides, a retroviral vector is constructed, slow viruses are packed, APC cells are transfected, and reformation of specificity LV cells is completed. PBMC obtained by in vitro and peripheral blood separation is cocultured, effective pinpoint polypeptide is screened, and through second impact of pinpoint polypeptide stimulation, common T cells are reformed to obtain LRFF cells having pinpoint killing capacity, and the killing capacity of the T cells to tumor cells can be improved. The LRFF provided by the invention can be widely applied to individual pinpoint treatment of solid tumors.

The application relates to AFFT1 cell and a preparation method thereof. The RFF cell is reformed by using TCR-T technical principle, the knock-out of the immunosuppression target spot is performed onthe reformed T cell by using gene editing technology, the condition that the specific lysis T cell is prevented from in-vivo suppression is precisely protected, and the lethality on the tumor cell bythe T cell is improved.

The invention relates to a preparation method of AFFT1 cells. RFF cells are transformed through a TCR-T technical principle, then immunosuppression target spots of transformed T cells are knocked outthrough a gene editing technology, thus the specific cytotoxic T cells are precisely protected against being inhibited in vivo, and the lethality of the T cells on tumor cells is improved.

The invention belongs to the field of biotechnology, and in particular relates to a method for constructing HAFFT1 cells. In this method, cells stimulated by small molecule-modified polypeptides are transformed with TCR-T technology, and the transformed T cells are then knocked out immunosuppressive targets, which accurately protects specific killer T cells from in vivo. Inhibition increases the killing power of T cells to tumor cells. The proportion of specific T cells (TCR+) recognizing tumor antigens in cells transformed by the HAFFT1 program was over 80%.